Radiotherapy and Tyrosine Kinase Inhibitors in Stage IV Non-small Cell Lung Cancer: Real-life Experience.

about

Radiotherapy and Tyrosine Kinase Inhibitors in Stage IV Non-small Cell Lung Cancer: Real-life Experience.

Item

http://www.wikidata.org/entity/Q47253056

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Radiotherapy and Tyrosine Kina ...... Cancer: Real-life Experience.

@en

Radiotherapy and Tyrosine Kina ...... Cancer: Real-life Experience.

@nl

type

Item

label

Radiotherapy and Tyrosine Kina ...... Cancer: Real-life Experience.

@en

Radiotherapy and Tyrosine Kina ...... Cancer: Real-life Experience.

@nl

prefLabel

Radiotherapy and Tyrosine Kina ...... Cancer: Real-life Experience.

@en

Radiotherapy and Tyrosine Kina ...... Cancer: Real-life Experience.

@nl

P1476

Radiotherapy and Tyrosine Kina ...... g Cancer: Real-life Experience

@en

P2093

Anna Baiguini

http://www.w3.org/2001/XMLSchema#string

Diana Greco

http://www.w3.org/2001/XMLSchema#string

Emiliano Salah

http://www.w3.org/2001/XMLSchema#string

Luca Triggiani

http://www.w3.org/2001/XMLSchema#string

Marco Lorenzo Bonù

http://www.w3.org/2001/XMLSchema#string

Niccolò Giaj Levra

http://www.w3.org/2001/XMLSchema#string

Sara Pedretti

http://www.w3.org/2001/XMLSchema#string

Stefano Maria Magrini

http://www.w3.org/2001/XMLSchema#string

P2860

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial.

Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib.

Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.

Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.

Radiotherapy plus EGFR TKIs in non-small cell lung cancer patients with brain metastases: an update meta-analysis.

Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.

Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors

The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.

P304

159-164

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21873/INVIVO.11219

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29275314

http://www.w3.org/2001/XMLSchema#string

P932

5892641

http://www.w3.org/2001/XMLSchema#string